| Attention deficit hyperactivity disorder
Dyanavel XR vs QuilliChew ER
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Dyanavel Xr vs Quillichew Er with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQuillichew Er has a higher rate of injection site reactions vs Dyanavel Xr based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Quillichew Er but not Dyanavel Xr, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dyanavel Xr
Quillichew Er
At A Glance
Oral
Once daily
CNS stimulant
Oral
Daily
CNS stimulant
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder Starting dose 2.5 mg or 5 mg once daily in the morning; may increase by 2.5-10 mg per day every 4-7 days based on clinical response; maximum 20 mg once daily.
Attention deficit hyperactivity disorder Starting dose 20 mg once daily orally in the morning for patients 6 years and above; titrate weekly in increments of 10 mg, 15 mg, or 20 mg; doses above 60 mg/day have not been studied and are not recommended.
Contraindications
- Known hypersensitivity to amphetamine or other components of DYANAVEL XR
- Concomitant use or within 14 days of stopping MAOIs (including linezolid or intravenous methylene blue) due to risk of hypertensive crisis
- Hypersensitivity to methylphenidate or other components of QuilliChew ER
- Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days following MAOI discontinuation
Adverse Reactions
Most common (>=2%) Epistaxis, allergic rhinitis, upper abdominal pain (in pediatric patients aged 6-12 years in controlled trial)
Serious Palpitations, tachycardia, elevated blood pressure, sudden death, myocardial infarction, psychotic episodes, overstimulation, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, anaphylaxis
Postmarketing Rhabdomyolysis, Raynaud's phenomenon, intestinal ischemia, dermatillomania, bruxism, formication, frequent or prolonged erections, alopecia
Most common (>=2%) Decreased appetite, aggression, emotional poverty, nausea, headache, weight decreased
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, severe hepatocellular injury, angioedema, anaphylactic reactions, convulsion, dyskinesia, serotonin syndrome, hallucination, mania, priapism, rhabdomyolysis, Raynaud's phenomenon
Pharmacology
Amphetamine is a non-catecholamine sympathomimetic amine CNS stimulant that blocks reuptake of norepinephrine and dopamine into the presynaptic neuron and increases release of these monoamines into the extraneuronal space; the mode of therapeutic action in ADHD is not known.
Methylphenidate is a CNS stimulant that blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space; the d-isomer is more pharmacologically active than the l-isomer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dyanavel Xr
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
Quillichew Er
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Dyanavel Xr
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Quillichew Er
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Dyanavel Xr
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Quillichew Er
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Dyanavel Xr.
No savings programs available for Quillichew Er.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Dyanavel XrView full Dyanavel Xr profile
Quillichew ErView full Quillichew Er profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.